Ocular Therapeutix Inc. Insider Trading

OCUL

⊜ Compare

Last 12 months

Insiders bought 461K and sold $3.3M on the open market.

93% of the selling was scheduled in advance under 10b5-1 plans.

Net open-market

−$2.83M

1 buy · 28 sales

Under a 10b5-1 plan

93%

of the value sold

Insiders who bought / sold

1 / 8

executives and directors

Last open-market buy

Feb 2026

Feb 20, 2026

Get an email when OCUL's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 8	Todd Anderman Chief Legal Officer	Sold10b5-1 plan	11,984	$7.29	87K	7.9%	Form 4
Oct 2	Peter Kaiser Chief Development Officer	Sold10b5-1 plan	9,990	$7.05	70K	3.8%	Form 4
Oct 2	Jeffrey S. Heier Chief Scientific Officer	Sold10b5-1 plan	10,869	$7.05	77K	3.4%	Form 4
Aug 31	Donald Notman Chief Operating Officer	SoldNo plan	1,099	$10.24	11K	0.3%	Form 4
Aug 24	Peter Kaiser Chief Development Officer	Sold10b5-1 plan	3,035	$10.77	33K	1.1%	Form 4
Aug 24	Sanjay Nayak Chief Strategy Officer	Sold10b5-1 plan	1,897	$10.78	20K	0.6%	Form 4
Aug 24	Jeffrey S. Heier Chief Scientific Officer	Sold10b5-1 plan	3,296	$10.78	36K	1.0%	Form 4
Aug 24	Pravin Dugel See Remarks	Sold10b5-1 plan	21,649	$10.77	233K	0.7%	Form 4
Jun 3	Nadia Waheed Chief Medical Officer	Sold10b5-1 plan	14,828	$8.27	123K	4.7%	Form 4
May 26	Pravin Dugel See Remarks	Sold10b5-1 plan	21,156	$8.20	173K	0.6%	Form 4
May 26	Peter Kaiser Chief Development Officer	Sold10b5-1 plan	2,967	$8.20	24K	1.1%	Form 4
May 26	Jeffrey S. Heier Chief Scientific Officer	Sold10b5-1 plan	3,018	$8.20	25K	0.9%	Form 4
May 26	Sanjay Nayak Chief Strategy Officer	Sold10b5-1 plan	1,858	$8.20	15K	0.6%	Form 4
Feb 23	Pravin Dugel See Remarks	Sold10b5-1 plan	20,056	$8.28	166K	0.6%	Form 4
Feb 23	Peter Kaiser Chief Development Officer	Sold10b5-1 plan	2,810	$8.28	23K	1.0%	Form 4
Feb 23	Jeffrey S. Heier Chief Scientific Officer	Sold10b5-1 plan	3,057	$8.28	25K	0.9%	Form 4
Feb 23	Sanjay Nayak Chief Strategy Officer	Sold10b5-1 plan	1,759	$8.28	15K	0.5%	Form 4
Feb 20	Nadia Waheed Chief Medical Officer	Sold10b5-1 plan	3,510	$7.74	27K	1.1%	Form 4
Feb 20	Richard L Md Lindstrom Director	Bought	60,229	$7.66	461K	32%	Form 4
Feb 12	Donald Notman Chief Operating Officer	SoldNo plan	11,446	$9.04	103K	3.0%	Form 4
Feb 12	Sanjay Nayak Chief Strategy Officer	Sold10b5-1 plan	10,348	$9.04	94K	3.0%	Form 4
Feb 12	Pravin Dugel See Remarks	Sold10b5-1 plan	124,882	$9.04	$1.13M	3.6%	Form 4
Feb 12	Nadia Waheed Chief Medical Officer	Sold10b5-1 plan	7,863	$9.04	71K	2.4%	Form 4
Feb 2 – 4	Donald Notman Chief Operating Officer	SoldNo plan 2 parts	11,490	$8.82 average	101K	3.0%	Form 4
Nov 24, 2025	Sanjay Nayak Chief Strategy Officer	Sold10b5-1 plan	1,878	$12.04	23K	0.7%	Form 4
Nov 24, 2025	Pravin Dugel See Remarks	Sold10b5-1 plan	19,530	$12.04	235K	0.6%	Form 4
Nov 24, 2025	Peter Kaiser Chief Development Officer	Sold10b5-1 plan	3,007	$12.02	36K	1.5%	Form 4
Nov 24, 2025	Jeffrey S. Heier Chief Scientific Officer	Sold10b5-1 plan	3,469	$12.04	42K	1.4%	Form 4
Nov 5, 2025	Namrata Saroj Chief Business Officer	Sold10b5-1 plan	25,865	$10.74	278K	13%	Form 4
Oct 8, 2025	Todd Anderman Chief Legal Officer	Sold10b5-1 plan	11,132	$12.34	137K	11%	Form 4
Oct 2, 2025	Peter Kaiser Chief Development Officer	Sold10b5-1 plan	9,653	$11.03	106K	4.7%	Form 4
Oct 2, 2025	Jeffrey S. Heier Chief Scientific Officer	Sold10b5-1 plan	10,502	$11.04	116K	4.0%	Form 4
Sep 2, 2025	Donald Notman See Remarks	SoldNo plan	1,066	$12.43	13K	0.3%	Form 4
Aug 25, 2025	Peter Kaiser Chief Development Officer	Sold10b5-1 plan	3,011	$12.04	36K	1.5%	Form 4
Aug 25, 2025	Sanjay Nayak Chief Strategy Officer	Sold10b5-1 plan	1,885	$12.04	23K	0.7%	Form 4
Aug 25, 2025	Jeffrey S. Heier Chief Scientific Officer	Sold10b5-1 plan	3,063	$12.04	37K	1.2%	Form 4
Aug 25, 2025	Pravin Dugel See Remarks	Sold10b5-1 plan	21,494	$12.04	259K	0.6%	Form 4
Jun 2, 2025	Nadia Waheed Chief Medical Officer	Sold10b5-1 plan	13,861	$8.05	112K	6.3%	Form 4
May 23, 2025	Sanjay Nayak Chief Strategy Officer	Sold10b5-1 plan	1,862	$7.17	13K	0.7%	Form 4
May 23, 2025	Peter Kaiser Chief Development Officer	Sold10b5-1 plan	2,974	$7.17	21K	1.4%	Form 4

Oct 810b5-1 plan
Todd Anderman
Chief Legal Officer · sold 11,984 at $7.29
87K
7.9% of stake
Oct 210b5-1 plan
Peter Kaiser
Chief Development Officer · sold 9,990 at $7.05
70K
3.8% of stake
Oct 210b5-1 plan
Jeffrey S. Heier
Chief Scientific Officer · sold 10,869 at $7.05
77K
3.4% of stake
Aug 31No plan
Donald Notman
Chief Operating Officer · sold 1,099 at $10.24
11K
0.3% of stake
Aug 2410b5-1 plan
Peter Kaiser
Chief Development Officer · sold 3,035 at $10.77
33K
1.1% of stake
Aug 2410b5-1 plan
Sanjay Nayak
Chief Strategy Officer · sold 1,897 at $10.78
20K
0.6% of stake
Aug 2410b5-1 plan
Jeffrey S. Heier
Chief Scientific Officer · sold 3,296 at $10.78
36K
1.0% of stake
Aug 2410b5-1 plan
Pravin Dugel
See Remarks · sold 21,649 at $10.77
233K
0.7% of stake
Jun 310b5-1 plan
Nadia Waheed
Chief Medical Officer · sold 14,828 at $8.27
123K
4.7% of stake
May 2610b5-1 plan
Pravin Dugel
See Remarks · sold 21,156 at $8.20
173K
0.6% of stake
May 2610b5-1 plan
Peter Kaiser
Chief Development Officer · sold 2,967 at $8.20
24K
1.1% of stake
May 2610b5-1 plan
Jeffrey S. Heier
Chief Scientific Officer · sold 3,018 at $8.20
25K
0.9% of stake
May 2610b5-1 plan
Sanjay Nayak
Chief Strategy Officer · sold 1,858 at $8.20
15K
0.6% of stake
Feb 2310b5-1 plan
Pravin Dugel
See Remarks · sold 20,056 at $8.28
166K
0.6% of stake
Feb 2310b5-1 plan
Peter Kaiser
Chief Development Officer · sold 2,810 at $8.28
23K
1.0% of stake
Feb 2310b5-1 plan
Jeffrey S. Heier
Chief Scientific Officer · sold 3,057 at $8.28
25K
0.9% of stake
Feb 2310b5-1 plan
Sanjay Nayak
Chief Strategy Officer · sold 1,759 at $8.28
15K
0.5% of stake
Feb 2010b5-1 plan
Nadia Waheed
Chief Medical Officer · sold 3,510 at $7.74
27K
1.1% of stake
Feb 20
Richard L Md Lindstrom
Director · bought 60,229 at $7.66
461K
32% of stake
Feb 12No plan
Donald Notman
Chief Operating Officer · sold 11,446 at $9.04
103K
3.0% of stake
Feb 1210b5-1 plan
Sanjay Nayak
Chief Strategy Officer · sold 10,348 at $9.04
94K
3.0% of stake
Feb 1210b5-1 plan
Pravin Dugel
See Remarks · sold 124,882 at $9.04
$1.13M
3.6% of stake
Feb 1210b5-1 plan
Nadia Waheed
Chief Medical Officer · sold 7,863 at $9.04
71K
2.4% of stake
Feb 2 – 4No plan
Donald Notman
Chief Operating Officer · sold 11,490 at avg $8.82
101K
3.0% of stake
Nov 24, 202510b5-1 plan
Sanjay Nayak
Chief Strategy Officer · sold 1,878 at $12.04
23K
0.7% of stake
Nov 24, 202510b5-1 plan
Pravin Dugel
See Remarks · sold 19,530 at $12.04
235K
0.6% of stake
Nov 24, 202510b5-1 plan
Peter Kaiser
Chief Development Officer · sold 3,007 at $12.02
36K
1.5% of stake
Nov 24, 202510b5-1 plan
Jeffrey S. Heier
Chief Scientific Officer · sold 3,469 at $12.04
42K
1.4% of stake
Nov 5, 202510b5-1 plan
Namrata Saroj
Chief Business Officer · sold 25,865 at $10.74
278K
13% of stake
Oct 8, 202510b5-1 plan
Todd Anderman
Chief Legal Officer · sold 11,132 at $12.34
137K
11% of stake
Oct 2, 202510b5-1 plan
Peter Kaiser
Chief Development Officer · sold 9,653 at $11.03
106K
4.7% of stake
Oct 2, 202510b5-1 plan
Jeffrey S. Heier
Chief Scientific Officer · sold 10,502 at $11.04
116K
4.0% of stake
Sep 2, 2025No plan
Donald Notman
See Remarks · sold 1,066 at $12.43
13K
0.3% of stake
Aug 25, 202510b5-1 plan
Peter Kaiser
Chief Development Officer · sold 3,011 at $12.04
36K
1.5% of stake
Aug 25, 202510b5-1 plan
Sanjay Nayak
Chief Strategy Officer · sold 1,885 at $12.04
23K
0.7% of stake
Aug 25, 202510b5-1 plan
Jeffrey S. Heier
Chief Scientific Officer · sold 3,063 at $12.04
37K
1.2% of stake
Aug 25, 202510b5-1 plan
Pravin Dugel
See Remarks · sold 21,494 at $12.04
259K
0.6% of stake
Jun 2, 202510b5-1 plan
Nadia Waheed
Chief Medical Officer · sold 13,861 at $8.05
112K
6.3% of stake
May 23, 202510b5-1 plan
Sanjay Nayak
Chief Strategy Officer · sold 1,862 at $7.17
13K
0.7% of stake
May 23, 202510b5-1 plan
Peter Kaiser
Chief Development Officer · sold 2,974 at $7.17
21K
1.4% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch OCUL, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with OCUL

CompareIntrinsic value

CARMCarisma Therapeutics Inc.

$0.00+100.00%60

XLOXilio Therapeutics, Inc.

$8.71+0.35%40

QTTBQ32 Bio Inc.

$8.97+2.40%60

AQSTAquestive Therapeutics Inc.

$3.80-2.06%10

ARCTArcturus Therapeutics Holdings Inc.

$10.87+13.94%13

GOSSGossamer Bio Inc.

$9.40+1.29%10

XOMAXOMA Corporation

€0.05-3.60%64

NKTRNektar Therapeutics Inc.

$38.48+1.91%25

Held by ETFs

OCUL is in 30 US ETFs. The largest of them, with OCUL's weight in each:

Spot a number that looks wrong? Check it in OCUL's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing OCUL

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.